

Henk Vergunst

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11100079/publications.pdf>

Version: 2024-02-01

18
papers

2,098
citations

471061

17
h-index

794141

19
g-index

21
all docs

21
docs citations

21
times ranked

2882
citing authors

#	ARTICLE	IF	CITATIONS
1	Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study. <i>European Urology</i> , 2013, 63, 597-603.	0.9	450
2	Prospective Multicentre Evaluation of PCA3 and TMPRSS2-ERG Gene Fusions as Diagnostic and Prognostic Urinary Biomarkers for Prostate Cancer. <i>European Urology</i> , 2014, 65, 534-542.	0.9	306
3	Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. <i>European Urology</i> , 2016, 70, 740-748.	0.9	292
4	Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3061-3070.	3.2	193
5	POSTERIOR TIBIAL NERVE STIMULATION AS NEUROMODULATIVE TREATMENT OF LOWER URINARY TRACT DYSFUNCTION. <i>Journal of Urology</i> , 2001, 166, 914-918.	0.2	191
6	THE USE OF ELECTRICAL DEVICES FOR THE TREATMENT OF BLADDER DYSFUNCTION: A REVIEW OF METHODS. <i>Journal of Urology</i> , 2004, 172, 846-851.	0.2	107
7	Percutaneous Tibial Nerve Stimulation as Neuromodulative Treatment of Chronic Pelvic Pain. <i>European Urology</i> , 2003, 43, 158-163.	0.9	85
8	Value of 3-T Multiparametric Magnetic Resonance Imaging and Magnetic Resonance-Guided Biopsy for Early Risk Restratification in Active Surveillance of Low-Risk Prostate Cancer. <i>Investigative Radiology</i> , 2014, 49, 165-172.	3.5	83
9	Phase II Marker Lesion Study With Intravesical Instillation of Apaziquone for Superficial Bladder Cancer: Toxicity and Marker Response. <i>Journal of Urology</i> , 2006, 176, 1349-1353.	0.2	67
10	Evaluation of Diffusion-Weighted MR Imaging at Inclusion in an Active Surveillance Protocol for Low-Risk Prostate Cancer. <i>Investigative Radiology</i> , 2013, 48, 152-157.	3.5	63
11	Choice between prostatectomy and radiotherapy when men are eligible for both: a randomized controlled trial of usual care vs decision aid. <i>BJU International</i> , 2013, 111, 564-573.	1.3	61
12	Cryosurgery for Prostate Cancer: an Update on Clinical Results of Modern Cryotechnology. <i>European Urology</i> , 2009, 55, 76-86.	0.9	45
13	Does a decision aid for prostate cancer affect different aspects of decisional regret, assessed with new regret scales? A randomized, controlled trial. <i>Health Expectations</i> , 2016, 19, 459-470.	1.1	39
14	Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2009, 27, 337-342.	1.2	35
15	Extracorporeal Shockwave Lithotripsy of Gallstones. <i>Annals of Surgery</i> , 1989, 210, 565-575.	2.1	30
16	In vivo assessment of shock-wave pressures. <i>Gastroenterology</i> , 1990, 99, 1467-1474.	0.6	23
17	Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up. <i>European Urology Focus</i> , 2019, 5, 407-415.	1.6	23
18	Functional and oncological outcomes of salvage cryosurgery for radiorecurrent prostate cancer. <i>BJU International</i> , 2021, 128, 46-56.	1.3	4